154 related articles for article (PubMed ID: 11001889)
1. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study.
Ruutu T; Volin L; Parkkali T; Juvonen E; Elonen E
Blood; 2000 Oct; 96(7):2391-8. PubMed ID: 11001889
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial.
Deeg HJ; Lin D; Leisenring W; Boeckh M; Anasetti C; Appelbaum FR; Chauncey TR; Doney K; Flowers M; Martin P; Nash R; Schoch G; Sullivan KM; Witherspoon RP; Storb R
Blood; 1997 May; 89(10):3880-7. PubMed ID: 9160697
[TBL] [Abstract][Full Text] [Related]
3. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: Improved long-term survival with triple prophylaxis.
Ruutu T; Nihtinen A; Niittyvuopio R; Juvonen E; Volin L
Cancer; 2018 Feb; 124(4):727-733. PubMed ID: 29112242
[TBL] [Abstract][Full Text] [Related]
5. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
[TBL] [Abstract][Full Text] [Related]
6. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
Leelasiri A; Greer JP; Stein RS; Goodman S; Brandt SA; Edwards JR; Wolff SN
Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565
[TBL] [Abstract][Full Text] [Related]
7. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I
Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
[TBL] [Abstract][Full Text] [Related]
8. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
Liesveld J; Duerst R; Rapoport A; Constine L; Abboud C; Packman C; Wedow L; Zwetsch L; McKenna B; Linder T; Silverman W; Swift S; Rowe J; DiPersio J
Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy.
Atkinson K; Biggs J; Concannon A; Dodds A; Young S; Wilson F; Ashby M; Downs K
Aust N Z J Med; 1991 Dec; 21(6):850-6. PubMed ID: 1818544
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
Koga Y; Nagatoshi Y; Kawano Y; Okamura J
Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
[TBL] [Abstract][Full Text] [Related]
11. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation.
Tseng LH; Lin MT; Hansen JA; Gooley T; Pei J; Smith AG; Martin EG; Petersdorf EW; Martin PJ
Blood; 1999 Oct; 94(8):2911-4. PubMed ID: 10515896
[TBL] [Abstract][Full Text] [Related]
12. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation.
Van Lint MT; Uderzo C; Locasciulli A; Majolino I; Scimé R; Locatelli F; Giorgiani G; Arcese W; Iori AP; Falda M; Bosi A; Miniero R; Alessandrino P; Dini G; Rotoli B; Bacigalupo A
Blood; 1998 Oct; 92(7):2288-93. PubMed ID: 9746766
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
[TBL] [Abstract][Full Text] [Related]
14. Low-dose cyclosporin A with short-term methotrexate for graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation from human leukocyte antigen-identical siblings: a prospective phase II study in Japanese patients.
Kohno A; Morishita Y; Iida H; Sakamaki H; Yokozawa T; Kitaori K; Ozeki K; Matsuo K; Sao H
Int J Hematol; 2006 Jul; 84(1):83-9. PubMed ID: 16867909
[TBL] [Abstract][Full Text] [Related]
15. De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival.
Wagner JL; Seidel K; Boeckh M; Storb R
Biol Blood Marrow Transplant; 2000; 6(6):633-9. PubMed ID: 11128814
[TBL] [Abstract][Full Text] [Related]
16. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
[TBL] [Abstract][Full Text] [Related]
17. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
Atkinson K; Downs K
Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?
Ringdén O; Horowitz MM; Sondel P; Gale RP; Biggs JC; Champlin RE; Deeg HJ; Dicke K; Masaoka T; Powles RL
Blood; 1993 Feb; 81(4):1094-101. PubMed ID: 8427991
[TBL] [Abstract][Full Text] [Related]
19. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
Bolwell B; Sobecks R; Pohlman B; Andresen S; Rybicki L; Kuczkowski E; Kalaycio M
Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival.
Ross M; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM; Smith EP; Snyder DS; Stein AS; Wong RM; Forman SJ; Blume KG; Chao NJ
Biol Blood Marrow Transplant; 1999; 5(5):285-91. PubMed ID: 10534058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
